Status:
COMPLETED
A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20-64 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to assess the efficacy on joint damage and safety in RA patients treated with DMARDs in a double blind, placebo controlled study.
Eligibility Criteria
Inclusion
- Clinically diagnosed as rheumatoid arthritis by the revised ACR criteria
- Those who have been treated with an adequate stable dose of either methotrexate, salazosulfapyridine or bucillamine
- Those who have at least one erosion on X-ray of hands, wrists or feet
Exclusion
- Those who have been treated with any biologic drugs or leflunomide
- Those who meet Class 4 with the Steinbrocker functional classification
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT00319917
Start Date
April 1 2006
End Date
October 1 2008
Last Update
August 21 2014
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chyugoku Region, Japan
2
Hokkaido Region, Japan
3
Hokuriku Region, Japan
4
Kansai Region, Japan